Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicentre, Open, Prospective, Randomised, Parallel-Group, Pharmacodynamic Equivalence Study on Intramuscular Versus Subcutaneous Applications of Triptorelin Pamoate (Pamorelin LA 11.25 mg) in Patients With Advanced Prostate Cancer.

Trial Profile

A Phase II, Multicentre, Open, Prospective, Randomised, Parallel-Group, Pharmacodynamic Equivalence Study on Intramuscular Versus Subcutaneous Applications of Triptorelin Pamoate (Pamorelin LA 11.25 mg) in Patients With Advanced Prostate Cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms PAMIS
  • Sponsors Ipsen

Most Recent Events

  • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004139).
  • 29 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 30 Jan 2012 Actual patient numbers amended from 100 to 102 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top